Skip to main content

Compass Therapeutics, Inc.

CMPX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001738021

In the last 90 days, Compass Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $363.4M in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Compass Therapeutics, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of CMPX: Q1 2024 compared with Q2 2024
MeasureQ1 2024Q2 2024Change
Holders7882+4
Shares94.6M92.9M−1.69M (−1.8%)
Value$187.2M$93.4M−$93.8M (−50.1%)

New holders (14)

Institutions that held Compass Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to CMPX in Q2 2024
InstitutionSharesValue% of portfolio
Ground Swell Capital, LLC124,394$124.4K0.12%
HRT Financial LP122,038$122.0K0.00%
Panagora Asset Management Inc68,268$68.3K0.00%
Gsa Capital Partners LLP65,922$66.0K0.00%
Corebridge Financial, Inc.54,868$54.9K0.00%
Virtu Financial LLC51,233$51.0K0.00%
Susquehanna International Group, LLP50,455$50.5K0.00%
LPL Financial LLC50,000$50.0K0.00%
Mirae Asset Global ETFs Holdings Ltd.45,556$45.6K0.00%
Cubist Systematic Strategies, LLC40,701$40.7K0.00%
TownSquare Capital, LLC19,195$19.2K0.00%
Point72 (DIFC) Ltd8,231$8.23K0.00%
Hartford Financial Management Inc.1,000$1.00K0.00%
Point72 Asia (Singapore) Pte. Ltd.391$3910.00%

Sold out (10)

Institutions that held Compass Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.